ArticleExpert opinion on biological therapy2020
Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.
Article in Expert opinion on biological therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.Clinical drug investigation · 2022Trial
- The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases.Journal of clinical medicine · 2022Article
- Risk Factors and Treatment Strategy for Retinal Vascular Occlusive Diseases.Journal of clinical medicine · 2022Review
- High-flow Nasal Oxygen Therapy in COVID-19 Critically Ill Patients with Acute Hypoxemic Respiratory Failure: A Prospective Observational Cohort Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022Article
- Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up.Therapeutic advances in musculoskeletal disease · 2022Article
- Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.Journal of clinical medicine · 2021Review
- The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing.Life sciences · 2021Review
- Observational
- Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact.Immunotherapy advances · 2021Review
- Biologic Therapy in COVID-19.Archivos de bronconeumologia · 2021Article
- COPD in Spain at the Start of a New Decade.Archivos de bronconeumologia · 2021Article
- Nanotheranostics against COVID-19: From multivalent to immune-targeted materials.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.Critical care (London, England) · 2020Article
- Familial Mediterranean Fever and COVID-19: Friends or Foes?Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.